March 3, 2026Open Access

Feasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma

Key Points

Median survival for patients with sarcomatoid mesothelioma undergoing surgery is under one year, highlighting poor outcomes.
A small subset of patients with FEV1 ≥80% show promising results using a multimodality treatment approach.
This analysis focuses on patients specifically selected for pleurectomy decortication as part of their treatment.
These findings may indicate a need for targeted therapy in select cases, yet further studies are warranted.

Abstract

As expected, the median survival for most patients with sarcomatoid histology who undergo surgery is under one year. However, a small subset of patients with FEV1 ≥80% do quite well using the multimodality approach.

Feasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma

Key Points

Abstract

Cite This Study